Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate. Issue 1 (24th September 2020)

• Record Type: Journal Article
• Authors: Le, Viet H.; O'Connor, Victoria V.; Li, Daneng; Melstrom, Laleh G.; Fong, Yuman; DiFronzo, Andrew L.
• Is Part Of: Journal of surgical oncology. Volume 123:Issue 1(2021)
• Page Start: 164
• Page End: 171
• Publication Date: 2020-09-24
• Subjects: cholangiocarcinoma neoadjuvant therapy -- cholangiocarcinoma treatment response -- extrahepatic cholangiocarcinoma -- intrahepatic cholangiocarcinoma -- perihilar cholangiocarcinoma; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26230
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Adjuvant chemotherapy for cholangiocarcinoma (CCA) has not been shown to gain significant improvements in survival. Factors contributing to suboptimal treatment response include aggressive disease biology and late clinical presentation. When feasible, surgical resection is the first line of treatment. Yet, recurrence remains high and long‐term survival is rare. Neoadjuvant therapy is an appealing approach, with oncologic advantages in allowing the treatment of occult systemic disease and selection of patients most likely to benefit from radical surgery. However, given the surgery‐first treatment paradigm for CCA, there is a paucity of data supporting neoadjuvant therapy. This review summarizes the current evidence on treatment response and margin‐negative (R0) resection rate associated with neoadjuvant therapy for CCA.